Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ: IVVD )

1.704 +0.014 (+0.86%)
Streaming Delayed Price Updated: 1:54 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Invivyd Announces Changes to Executive Team
From Invivyd
Via GlobeNewswire
INVIVYD ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Invivyd, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IVVD, ADGI
From Rosen Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Invivyd, Inc. (IVVD) f/k/a Adagio Therapeutics, Inc.
From Robbins LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
IVVD INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
From Invivyd
Via GlobeNewswire
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
From Invivyd
Via GlobeNewswire
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
From Invivyd
Via GlobeNewswire
NASDAQ:IVVD Investor Alert: Investigation over Potential Wrongdoing at Invivyd, Inc.
San Diego, CA -- (SBWIRE) -- 11/11/2022 -- Certain directors of Invivyd, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Invivyd
Via GlobeNewswire
Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
From Invivyd
Via GlobeNewswire
Why Snap Shares Are Trading Sharply Lower; Here Are 25 Stocks Moving Premarket
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 40.9% to $0.2160 in pre-market trading. Statera Biopharma recently signed a binding Memorandum of Understanding with Holobeam Technologies Inc. 
Via Benzinga
AT&T, IBM, Las Vegas Sands And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares climbed 107.3% to close at $0.4138 on Thursday after the company announced its NextFintech division received commitment for a $15 million... 
Via Benzinga
Invivyd, Inc. (NASDAQ:IVVD) Shareholder Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 10/17/2022 -- Invivyd, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Why Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday's Mid-Day Session
Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares jumped 126% to $0.4525 after the company announced its NextFintech division received commitment for a $15 million strategic investment. 
Via Benzinga
US Stock Futures Edge Lower Following Thursday's Rally; Big Bank Earnings In Focus
Pre-open movers 
Via Benzinga
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
From Invivyd
Via GlobeNewswire
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
From Invivyd
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.